Skip to main content

C1 inhibitor attenuates pulmonary inflammation in an in vivo model of transfusion-related acute lung injury

Introduction

Transfusion-related acute lung injury (TRALI) has a high incidence in critically ill and surgical patients and contributes to adverse outcome, while specific therapy is absent. Recently it was demonstrated that complement activation plays a pivotal role in TRALI. We aimed to determine whether a C1 inhibitor is beneficial in a two-hit mouse model of antibody-mediated TRALI.

Methods

BALB/c mice were primed with lipopolysaccharide (LPS, from E. coli 0111:B4) that was administered intraperitoneally in a dose of 0.1 mg/kg, after which TRALI was induced by injecting MHC-I antibody against H2Kd (IgG2a,k) at a dose of 2 mg/kg. Mice infused with PBS or LPS served as controls. Concomitantly, mice infused with the MHC-I antibody were treated with C1 inhibitor (Cetor®; Sanquin, Amsterdam, the Netherlands) in a dose of 400 IU/kg intravenously. After infusion, mice were mechanically ventilated with a lung-protective pressure-controlled mode for 2 hours and then sacrificed, after which a bronchoalveolar lavage (BAL) was done. Statistics were analyzed by one-way ANOVA, values expressed as mean and standard deviation.

Results

Injection of LPS and MHC-I antibodies resulted in TRALI, indicated by increased levels of protein in the BAL fluid, wet/dry ratios and levels of KC, MIP-2 and IL-6. C1 inhibitor Cetor® significantly reduced total protein in BAL fluid from 792 (169) to 421 (230) μg/ml (P < 0.001) and tended to reduce the wet/dry ratio from 5.3 ± 0.3 to 4.9 ± 0.5 (P = 0.09). Cetor® also reduced BALF levels of MIP-2 from 214 (54) to 127 (22) pg/ml (P < 0.01). KC and IL-6 levels were not affected.

Conclusion

In a model of antibody-mediated TRALI, C1 inhibitor attenuated pulmonary inflammation. C1 inhibition may be a potential beneficial intervention in TRALI.

Author information

Affiliations

Authors

Corresponding author

Correspondence to M Müller.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Müller, M., Tuinman, P., Jongsma, G. et al. C1 inhibitor attenuates pulmonary inflammation in an in vivo model of transfusion-related acute lung injury. Crit Care 17, P372 (2013). https://doi.org/10.1186/cc12310

Download citation

Keywords

  • Mouse Model
  • Total Protein
  • Emergency Medicine
  • Pivotal Role
  • Adverse Outcome